Silvercrest Asset Management’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$44.3M Buy
90,091
+16,669
+23% +$9.05M 0.32% 82
2025
Q4
$42.5M Sell
73,422
-11,165
-13% -$6.31M 0.29% 96
2025
Q3
$41M Buy
84,587
+43,147
+104% +$20.1M 0.27% 112
2025
Q2
$16.8M Sell
41,440
-410
-1% -$171K 0.11% 227
2025
Q1
$20.8M Buy
41,850
+807
+2% +$437K 0.15% 179
2024
Q4
$21.4M Sell
41,043
-480
-1% -$264K 0.14% 177
2024
Q3
$25.7M Buy
41,523
+11
+0% +$6.51K 0.17% 168
2024
Q2
$23M Sell
41,512
-4,118
-9% -$2.36M 0.16% 170
2024
Q1
$26.5M Buy
45,630
+1,053
+2% +$591K 0.18% 158
2023
Q4
$23.7M Buy
44,577
+958
+2% +$464K 0.17% 162
2023
Q3
$22.1M Buy
43,619
+106
+0.2% +$56.5K 0.17% 162
2023
Q2
$22.7M Buy
43,513
+1,435
+3% +$774K 0.16% 163
2023
Q1
$24.3M Sell
42,078
-129
-0.3% -$72.7K 0.18% 148
2022
Q4
$23.2M Buy
42,207
+460
+1% +$244K 0.18% 149
2022
Q3
$21.2M Sell
41,747
-1,036
-2% -$580K 0.17% 156
2022
Q2
$23.2M Sell
42,783
-2,224
-5% -$1.22M 0.18% 155
2022
Q1
$26.6M Buy
45,007
+662
+1% +$380K 0.17% 160
2021
Q4
$29.6M Sell
44,345
-1,151
-3% -$719K 0.19% 145
2021
Q3
$26M Sell
45,496
-310
-0.7% -$170K 0.18% 153
2021
Q2
$23.1M Sell
45,806
-284
-0.6% -$134K 0.15% 174
2021
Q1
$21M Buy
46,090
+9,358
+25% +$4.47M 0.14% 178
2020
Q4
$17.1M Sell
36,732
-1,150
-3% -$539K 0.12% 184
2020
Q3
$16.7M Sell
37,882
-352
-0.9% -$145K 0.14% 165
2020
Q2
$13.9M Buy
38,234
+1,327
+4% +$445K 0.12% 174
2020
Q1
$10.5M Sell
36,907
-180
-0.5% -$56.8K 0.11% 187
2019
Q4
$12M Sell
37,087
-213
-0.6% -$64.6K 0.09% 212
2019
Q3
$10.9M Hold
37,300
0.09% 215
2019
Q2
$11M Buy
37,300
+389
+1% +$107K 0.1% 170
2019
Q1
$10.1M Sell
36,911
-553
-1% -$138K 0.1% 173
2018
Q4
$8.38M Sell
37,464
-194
-0.5% -$45.5K 0.09% 181
2018
Q3
$9.19M Sell
37,658
-56
-0.1% -$12.9K 0.08% 186
2018
Q2
$7.81M Buy
37,714
+692
+2% +$147K 0.07% 202
2018
Q1
$7.64M Sell
37,022
-97
-0.3% -$20.4K 0.07% 198
2017
Q4
$7.05M Buy
37,119
+1,482
+4% +$284K 0.07% 207
2017
Q3
$6.74M Buy
35,637
+675
+2% +$122K 0.07% 200
2017
Q2
$6.1M Buy
34,962
+172
+0.5% +$28.9K 0.07% 205
2017
Q1
$5.34M Sell
34,790
-676
-2% -$103K 0.06% 216
2016
Q4
$5M Sell
35,466
-849
-2% -$125K 0.06% 219
2016
Q3
$5.78M Sell
36,315
-988
-3% -$152K 0.07% 207
2016
Q2
$5.51M Buy
37,303
+832
+2% +$123K 0.07% 203
2016
Q1
$5.16M Sell
36,471
-1,603
-4% -$215K 0.07% 199
2015
Q4
$5.4M Buy
38,074
+15,273
+67% +$2.04M 0.07% 206
2015
Q3
$2.79M Sell
22,801
-15,814
-41% -$2.06M 0.04% 236
2015
Q2
$5.01M Buy
38,615
+16,450
+74% +$2.14M 0.07% 222
2015
Q1
$2.98M Sell
22,165
-1,625
-7% -$209K 0.04% 237
2014
Q4
$2.98M Buy
23,790
+2,000
+9% +$243K 0.04% 244
2014
Q3
$2.65M Hold
21,790
0.04% 247
2014
Q2
$2.57M Buy
21,790
+2,792
+15% +$329K 0.04% 250
2014
Q1
$2.28M Sell
18,998
-200
-1% -$23.8K 0.04% 252
2013
Q4
$2.14M Buy
19,198
+741
+4% +$73.7K 0.04% 260
2013
Q3
$1.7M Buy
18,457
+2,170
+13% +$196K 0.03% 269
2013
Q2
$1.38M Buy
+16,287
New +$1.36M 0.03% 277

Other funds holding TMO

Silvercrest Asset Management's TMO Position: Q1 2026 in Review

Silvercrest Asset Management increased its Thermo Fisher Scientific (TMO) stake by 23% in Q1 2026, buying an estimated $9.05M and bringing the position to 90,091 shares worth $44.3M. The position accounts for 0.32% of the portfolio, ranked #82.

Silvercrest Asset Management first reported a position in TMO in Q2 2013 and has held it in 52 quarters since. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Silvercrest Asset Management held 90,091 shares of Thermo Fisher Scientific worth $44.3M as of Q1 2026.
  • Silvercrest Asset Management bought 16,669 Thermo Fisher Scientific shares in Q1 2026, an estimated $9.05M.
  • Thermo Fisher Scientific made up 0.32% of Silvercrest Asset Management's portfolio in Q1 2026, its #82 holding.
  • Silvercrest Asset Management first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 52 quarters since.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Silvercrest Asset Management's 13F filing for Q1 2026, filed 15 May 2026.